Omigapil (maleate)

Omigapil maleate (CGP3466B), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil maleate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].

Product Specifications

CAS Number

[200189-97-5]

Product Name Alternative

CGP3466B; CGP3446 (maleate) ; TCH346 (maleate)

UNSPSC

12352005

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/omigapil-maleate.html

Purity

99.84

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

C#CCN(C)CC1=CC2=CC=CC=C2OC3=CC=CC=C13.O=C(O)/C=C\C(O)=O

Molecular Formula

C23H21NO5

Molecular Weight

391.42

References & Citations

[1]Sarina Meinen, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3 (8) :465-79.|[2]Tanusree Sen, et al. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11 (522) :eaao6765.